Loading company…
Windward Bio develops antibody therapies for severe immunological and respiratory diseases.
Windward Bio develops therapies for severe immunological diseases, including asthma and chronic obstructive pulmonary disease. Its programs include WIN378, an antibody targeting TSLP, and long-acting bispecific antibodies. Based in Basel, Switzerland, the company raised USD 165 million in May 2026 to advance clinical programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in